4,5-Dihydroxycyclohex-1-enecarboxylic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 4,5-Dihydroxycyclohex-1-enecarboxylic acid
• 英文别名: 4,5-dihydroxycyclohexene-1-carboxylic acid
• 化学式: C₇H₁₀O₄
• 分子量: 158.15
• InChiKey: ZJFDZKAGRTZFDZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• [EN] NOVEL MACROCYCLES AND METHODS FOR THEIR PRODUCTION<br/>[FR] NOUVEAUX MACROCYLES ET LEURS PROCÉDÉS DE PRODUCTION
  申请人：BIOTICA TECH LTD

  公开号：WO2011045594A1

  公开（公告）日：2011-04-21

  There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R4 and X are as described in the description, said compounds being useful as anti-inflammatory agents with reduced system effect.

  提供的化合物具有以下式（I）或其药用盐：其中变量R1-R4和X如描述中所述，这些化合物可用作具有减少系统效应的抗炎药物。
• [EN] NOVEL MACROCYLES AND METHODS FOR THEIR PRODUCTION<br/>[FR] NOUVEAUX MACROCYLES ET LEURS PROCÉDÉS DE PRODUCTION
  申请人：BIOTICA TECH LTD

  公开号：WO2011045593A1

  公开（公告）日：2011-04-21

  There are provided compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein the variables R1-R3 are as described in the description, said compounds being useful as anti-inflammatory agents with reduced systemic effects.

  提供了化合物的结构式（I）或其药用盐：其中变量R1-R3如描述中所述，这些化合物可用作具有减少全身效应的抗炎药物。
• NOVEL TACROLIMUS ANALOGUES, A NEUROPROTECTIVE COMPOSITION COMPRISING THE SAME, AN IMMUNOSUPPRESSIVE COMPOSITION COMPRISING THE SAME, A METHOD FOR PREPARING THE SAME, AND A MUTANT FOR PRODUCING THE SAME
  申请人：EWHA UNIVERSITY- INDUSTRY COLLABORATION FOUNDATION

  公开号：US20130230559A1

  公开（公告）日：2013-09-05

  The present invention relates to novel tacrolimus analogues, a composition for the prevention or treatment of neurological diseases or immune hypersensitivity disorders comprising the same, a method for preventing or treating neurological diseases or immune hypersensitivity disorders comprising administering the analogues to a subject, a method for preparing the analogues using an isolated modified Streptomyces sp. strain wherein the activity of one or more enzymes selected from the group consisting of TcsA, TcsB, TcsC and TcsD is reduced; and the isolated modified Streptomyces sp. strain for prepare the analogues.

  本发明涉及新型他克莫司类似物，一种用于预防或治疗神经疾病或免疫过敏性疾病的组合物，包括相同的组成部分，一种通过向受试者施用类似物来预防或治疗神经疾病或免疫过敏性疾病的方法，一种使用经过改良的分离链霉菌菌株制备类似物的方法，其中来自于TcsA、TcsB、TcsC和TcsD组中选择的一个或多个酶的活性被降低；以及用于制备类似物的经过改良的分离链霉菌菌株。
• [EN] MTORC MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE MTORC ET LEURS UTILISATIONS
  申请人：AEOVIAN PHARMACEUTICALS INC

  公开号：WO2020154447A1

  公开（公告）日：2020-07-30

  Novel rapamycin analogs and uses thereof are disclosed herein. The rapamycin analogs of the present disclosure show increased mTORC1 specificity and lowered mTORC2 specificity relative to rapamycin.

  本文披露了新型雷帕霉素类似物及其用途。本公开的雷帕霉素类似物相对于雷帕霉素表现出增加的mTORC1特异性和降低的mTORC2特异性。
• [EN] FK506 AND FK520 ANALOGUES AND THEIR PHARMACEUTICAL USES<br/>[FR] ANALOGUES DE FK506 ET PK520 ET LEURS UTILISATIONS PHARMACEUTIQUES
  申请人：BIOTICA TECH LTD

  公开号：WO2010106366A1

  公开（公告）日：2010-09-23

  The present invention relates to novel FK506 and FK520 analogues and strains generated by replacing the natural loading module of the FK506 or FK520 polyketide synthase (PKS) with the avermectin or an avermectin-like PKS loading module and optionally feeding non-natural starter units to these strains and to use of such compounds in therapy.

  本发明涉及新颖的FK506和FK520类似物以及通过使用avermectin或类似于avermectin的多酮合成酶（PKS）的装载模块替换FK506或FK520 PKS的自然装载模块并可选择性地向这些菌株提供非自然起始单元而生成的菌株，以及这些化合物在治疗中的应用。